维布妥昔单抗联合环磷酰胺、丙卡巴肼、泼尼松、依托泊苷和米托蒽醌(BrEPEM)方案治疗老年初治经典霍奇金淋巴瘤的Ib/II期多中心GELTAMO试验
这项Ib/II期多中心单臂研究评估BrEPEM方案治疗40例老年初治经典霍奇金淋巴瘤患者的安全性和疗效,中位年龄73岁,93%为III/IV期。最常见不良事件为血液学毒性(中性粒细胞减少G≥3:32%),治疗期间5例死于感染。按方案/意向治疗分析总缓解率分别为93%/63%,完全缓解率分别为89%/60%;中位无进展生存期14.3个月,中位总生存期未达到。作者认为BrEPEM是老年初治患者的一种替代选择,但并非没有毒性,需要更好的患者选择研究。
要点
- BrEPEM方案治疗老年初治cHL:按方案分析总缓解率93%,完全缓解率89%。
- 意向治疗分析总缓解率63%,完全缓解率60%。
- 中性粒细胞减少G≥3发生率为32%,治疗期间5例死于感染。
核心结论
- BrEPEM是老年初治经典霍奇金淋巴瘤患者的一种替代选择,但并非没有毒性。
- 需要针对更好患者选择的研究来改善生存并减轻毒性。
研究设计与样本
- Ib/II期多中心单臂研究,共纳入40例患者(Ib期6例,II期34例)。
- 研究对象为老年初治经典霍奇金淋巴瘤患者,中位年龄73岁(范围67-88岁),93%为III/IV期,中位CIRS-G评分为5(范围1-28)。
- 中位随访时间为43.2个月。
主要发现
- 最常见不良事件为血液学毒性,中性粒细胞减少G≥3发生率为32%。
- 治疗期间5例患者死于感染。
- 按方案分析总缓解率为93%,完全缓解率为89%;意向治疗分析总缓解率为63%,完全缓解率为60%。
- 中位无进展生存期为14.3个月(95%CI=11.5-未达到),中位总生存期未达到(95%CI=29.5-未达到)。
- 估计2年无进展生存率为44%(95%CI=31-62),2年总生存率为69%(95%CI=56-85)。
临床怎么用
- 作者认为BrEPEM是老年初治经典霍奇金淋巴瘤患者的一种替代选择,但并非没有毒性。
- 作者建议需要针对更好患者选择的研究来改善生存并减轻毒性。
局限性
- 治疗期间5例患者死于感染,方案并非没有毒性。
- 需要针对更好患者选择的研究来改善生存并减轻毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classical Hodgkin lymphoma (cHL) has high curability following initial standard treatments. A less favourable outcome is observed in patients aged ≥60 (poorer tolerability and efficacy). Low-intensity chemotherapies are currently employed for this group of patients, although there is still a need for improvement. This phase Ib/II multicentre, single-arm study evaluated the safety and efficacy of the combination of brentuximab vedotin with cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone (BrEPEM) in older untreated patients with cHL. Forty patients were enrolled (6 phase Ib; 34 phase II). Median age was 73 years (range: 67-88), 93% stage III/IV and median Cumulative Illness Rating Scale-Geriatric (CIRS-G) was 5 (range: 1-28). The median follow-up was 43.2 months. The most common adverse events were haematological toxicities (neutropenia G ≥3: 32%). During treatment, five patients died from infections. Per protocol/intention-to-treat analysis showed an overall response of 93%/63% and a complete response of 89%/60% respectively. Median progression-free survival (PFS) and overall survival (OS) were 14.3 months (95% confidence interval [CI] = 11.5-not reached [NR]) and NR (95% CI = 29.5-NR) respectively. Estimated 2-year PFS and OS were 44% (95% CI = 31-62) and 69% (95% CI = 56-85) respectively. BrEPEM is an alternative option for older untreated cHL patients, albeit not exempt from toxicity. Studies directed to better patient selection are needed to improve survival and mitigate toxicities.
引用
- Carpio C, de la Cruz-Vicente F, García-Sanz R, et al. A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial. Br J Haematol. 2025. PMID: 40714959. doi:10.1111/bjh.70028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。